Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index; 34 of the 57 sources its claims cite were checked for support.

Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians.

Open access
Nguyen, Julia, Brantley,., Milam A., Schwartz, Stephen G · 2024 · Frontiers in Bioscience-Scholar

Abstract

Age-related macular degeneration (AMD) is a multifactorial genetic disease, with at least 52 identifiable associated gene variants at 34 loci, including variants in complement factor H (CFH) and age-related maculopathy susceptibility 2/high-temperature requirement A serine peptidase-1 (ARMS2/HTRA1). Genetic factors account for up to 70% of disease variability. However, population-based genetic risk scores are generally more helpful for clinical trial design and stratification of risk groups than for individual patient counseling. There is some evidence of pharmacogenetic influences on various treatment modalities used in AMD patients, including Age-Related Eye Disease Study (AREDS) supplements, photodynamic therapy (PDT), and anti-vascular endothelial growth factor (anti-VEGF) agents. However, there is currently no convincing evidence that genetic information plays a role in routine clinical care.

Overview

CoChat Summary

TL;DR

This narrative review summarizes age-related macular degeneration (AMD) genetics and pharmacogenetics, noting that AMD is highly polygenic with genetic factors accounting for up to 70% of disease variability. It concludes that genetic testing is not indicated in routine AMD care because pharmacogenetic associations remain inconsistent and largely unreplicated.

Key findings

  • AMD has at least 52 independently associated variants across 34 loci, including CFH and ARMS2/HTRA1; the IAMDGC GWAS included 16,144 AMD patients and 17,832 controls, and a TWAS in the same cohorts reported 106 genes significantly associated with AMD in at least one tissue, including 28 in tibial nerve, 28 in subcutaneous adipose, and 26 in lung tissue.
  • Pharmacogenetic associations have been reported for anti-VEGF agents, PDT, and AREDS/AREDS 2 nutritional supplementation, but findings are inconsistent: two large multicenter randomized clinical trials could not replicate anti-VEGF pharmacogenetic findings, and a 2022 review of 41 observational series, 7 meta-analyses, and 5 GWAS reported no consistent patterns.
  • A 2022 meta-analysis of 33 case-control series concluded that variants at CFH, ARMS2/HTRA1, and OR52B4 were significantly associated with anti-VEGF response, while AREDS analyses conflicted: an initial retrospective analysis of 876 patients suggested CFH-related differences, but AREDS investigators could not replicate findings in a 526-participant residual cohort, and AREDS 2 investigators found no significant CFH/ARMS2 interaction in 1,684 patients.
  • Population-based genetic risk scores are described as useful for clinical trial design and risk stratification, but not for individual patient counseling; the authors state there is no convincing evidence that genetic information improves routine clinical outcomes and that they do not use commercially available AMD genetic testing in practice.

Methods

  • Design: narrative review for clinicians, not a systematic review or meta-analysis.
  • Data: cited literature on AMD genetics and pharmacogenetics, including GWAS, TWAS, randomized trials, observational series, meta-analyses, and a selected recent pharmacogenetic association table.
  • Analysis: narrative synthesis of reported genetic associations and clinical implications, with no formal search strategy, quality appraisal, or primary data analysis described.

Limitations

  • Stated: pharmacogenetic results are inconsistent and frequently conflicting, potentially due to baseline population differences, small sample sizes, heterogeneous treatment protocols, and differences in outcome measures; the paper notes that at least 15,000 patients may be needed to definitively identify genetic associations with anti-VEGF response.
  • Stated: there is currently no convincing evidence that using genetic information improves clinical outcomes, and no indication to perform genetic sequencing on patients with AMD.
  • Evident: as a narrative review, it relies on selected studies and a selected table rather than a systematic literature search, and it does not provide new primary data or formal risk-of-bias assessment.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.31083/j.fbs1601003

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

24 Valid · 1 Not valid · 12 Not checked · 6 Own results and interpretations

27 more claims · 14 with their cited sources checked

Create a free account to see all 43 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 8
  • Probably not a substantial claim. 2
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Citations

Cites

Show all 68 references

Research works printed but not linked: 2

  1. Teper SJ, Nowinska A, Pilat J, Palucha A, Wylegala E. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Molecular Vision. 2010; 16: 2598–2604.
  2. Nakai S, Honda S, Matsumiya W, Miki A, Nakamura M. ARMS2 variants may predict the 3-year outcome of photodynamic therapy for wet age-related macular degeneration. Molecular Vision. 2017; 23: 514–519.

Cited by

See all 12

Metadata

Authors
Nguyen, J., Brantley, & Schwartz, S. G.
Affiliations
  • Rutgers New Jersey Medical School (US)
  • Vanderbilt University Medical Center (US)
  • University of Miami (US)
Corresponding author
Schwartz, Stephen G
Venue
Frontiers in Bioscience-Scholar
Publisher
IMR Press
Published
2024-02-29
Volume
16
Issue
1
Pages
3-3
ISSN
  • 1944-7906 (ISSN-L)
  • 1945-0516
  • 1945-0524
OpenAlex
W4392366336
Cited by
12
References
68
Citations by year
2026: 6 · 2025: 4 · 2024: 2
FWCI
0.98
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Bioscience-Scholar (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • NIH Core Center (P30EY014801)
  • Research to Prevent Blindness-Unrestricted (GR004596-1)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
Keywords
age-related macular degeneration, genetic susceptibility, genetic susceptibility loci, complement factor H, polygenic risk score, pharmacogenetics, photodynamic therapy, anti-VEGF therapy, patient counseling
MeSH terms
High-Temperature Requirement A Serine Peptidase 1, Humans, Macular Degeneration, Proteins, Risk Factors, Dietary Supplements, Polymorphism, Single Nucleotide, Vascular Endothelial Growth Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. https://app.cochat.ai/papers/10.31083/j.fbs1601003
The paper
Nguyen, J., Brantley, & Schwartz, S. G. (2024). Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. Frontiers in Bioscience-Scholar. https://doi.org/10.31083/j.fbs1601003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.